CD8A and lung carcinoma: For instance, a panel could select genes that are key markers for immune cell types in a particular cancer, such as CD8+ T cells or tumor-associated macrophages (TAMs) in lung cancer, to assess immune infiltration and cancer immunotherapy targets [30].